COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
<p dir="ltr">Large scale multi-omics analysis has identified significant differences in the biomarkers between COVID-19 disease and control subjects [1]. These protein panels target biological processes involved in vessel damage, platelet degranulation, the coagulation cascade and th...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Published: |
2020
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513517551353856 |
|---|---|
| author | Abu Saleh Md Moin (6189512) |
| author2 | Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| author2_role | author author author |
| author_facet | Abu Saleh Md Moin (6189512) Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| author_role | author |
| dc.creator.none.fl_str_mv | Abu Saleh Md Moin (6189512) Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| dc.date.none.fl_str_mv | 2020-12-22T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1186/s12967-020-02669-2 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/COVID-19_biomarkers_for_severity_mapped_to_polycystic_ovary_syndrome/25709766 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Clinical sciences Large scale multi-omics analysis Biomarkers COVID-19 disease Protein panels Vessel damage Platelet degranulation Polycystic ovary syndrome (PCOS) |
| dc.title.none.fl_str_mv | COVID-19 biomarkers for severity mapped to polycystic ovary syndrome |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Large scale multi-omics analysis has identified significant differences in the biomarkers between COVID-19 disease and control subjects [1]. These protein panels target biological processes involved in vessel damage, platelet degranulation, the coagulation cascade and the acute phase response [1], with greater protein changes dependent on the COVID-19 severity. However, it is observed that in metabolic conditions such as polycystic ovary syndrome expressed proteins differ compared to control women [2] and PCOS patients have increased platelet aggregation and decreased plasma fibrinolytic activity, resulting in a prothrombotic propensity [3, 4], with elevated coagulation markers [5]. Therefore, any biomarkers reflecting COVID-19 disease and its severity would necessarily have to be independent of differentially-expressed proteins relating to other conditions; therefore, this proteomic analysis was undertaken in women with and without PCOS to compare with the proteomic biomarkers recently described in COVID-19 using shotgun proteomics followed by parallel reaction monitoring [1].</p><p dir="ltr">146 PCOS and 97 control women who presented sequentially to the Department of Endocrinology, Hull and East Yorkshire Hospitals NHS Trust were recruited to the local PCOS biobank (ISRCTN70196169) [2]. PCOS diagnosis was based on all three Rotterdam consensus diagnostic criteria. Proteins that were identified as being altered in COVID-19 disease for vessel damage (16 proteins), platelet degranulation (11 proteins), coagulation cascade (24 proteins) and acute phase response (9 proteins), shown in Table 1, were determined by Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement [6]. Statistics were performed using Graphpad Prism 8.0.</p><p dir="ltr">Correction: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome: <a href="https://doi.org/10.1186/s12967-021-02782-w" rel="noreferrer" target="_blank">https://doi.org/10.1186/s12967-021-02782-w</a>, published online 15 March 2021.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Translational Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s12967-020-02669-2" target="_blank">https://dx.doi.org/10.1186/s12967-020-02669-2</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_7c1d3a2bfeb92a6d305cc1946a3a6657 |
| identifier_str_mv | 10.1186/s12967-020-02669-2 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25709766 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | COVID-19 biomarkers for severity mapped to polycystic ovary syndromeAbu Saleh Md Moin (6189512)Thozhukat Sathyapalan (704787)Stephen L. Atkin (6684368)Alexandra E. Butler (6189536)Biological sciencesBiochemistry and cell biologyBiomedical and clinical sciencesClinical sciencesLarge scale multi-omics analysisBiomarkersCOVID-19 diseaseProtein panelsVessel damagePlatelet degranulationPolycystic ovary syndrome (PCOS)<p dir="ltr">Large scale multi-omics analysis has identified significant differences in the biomarkers between COVID-19 disease and control subjects [1]. These protein panels target biological processes involved in vessel damage, platelet degranulation, the coagulation cascade and the acute phase response [1], with greater protein changes dependent on the COVID-19 severity. However, it is observed that in metabolic conditions such as polycystic ovary syndrome expressed proteins differ compared to control women [2] and PCOS patients have increased platelet aggregation and decreased plasma fibrinolytic activity, resulting in a prothrombotic propensity [3, 4], with elevated coagulation markers [5]. Therefore, any biomarkers reflecting COVID-19 disease and its severity would necessarily have to be independent of differentially-expressed proteins relating to other conditions; therefore, this proteomic analysis was undertaken in women with and without PCOS to compare with the proteomic biomarkers recently described in COVID-19 using shotgun proteomics followed by parallel reaction monitoring [1].</p><p dir="ltr">146 PCOS and 97 control women who presented sequentially to the Department of Endocrinology, Hull and East Yorkshire Hospitals NHS Trust were recruited to the local PCOS biobank (ISRCTN70196169) [2]. PCOS diagnosis was based on all three Rotterdam consensus diagnostic criteria. Proteins that were identified as being altered in COVID-19 disease for vessel damage (16 proteins), platelet degranulation (11 proteins), coagulation cascade (24 proteins) and acute phase response (9 proteins), shown in Table 1, were determined by Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement [6]. Statistics were performed using Graphpad Prism 8.0.</p><p dir="ltr">Correction: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome: <a href="https://doi.org/10.1186/s12967-021-02782-w" rel="noreferrer" target="_blank">https://doi.org/10.1186/s12967-021-02782-w</a>, published online 15 March 2021.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Translational Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s12967-020-02669-2" target="_blank">https://dx.doi.org/10.1186/s12967-020-02669-2</a></p>2020-12-22T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1186/s12967-020-02669-2https://figshare.com/articles/journal_contribution/COVID-19_biomarkers_for_severity_mapped_to_polycystic_ovary_syndrome/25709766CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257097662020-12-22T03:00:00Z |
| spellingShingle | COVID-19 biomarkers for severity mapped to polycystic ovary syndrome Abu Saleh Md Moin (6189512) Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Clinical sciences Large scale multi-omics analysis Biomarkers COVID-19 disease Protein panels Vessel damage Platelet degranulation Polycystic ovary syndrome (PCOS) |
| status_str | publishedVersion |
| title | COVID-19 biomarkers for severity mapped to polycystic ovary syndrome |
| title_full | COVID-19 biomarkers for severity mapped to polycystic ovary syndrome |
| title_fullStr | COVID-19 biomarkers for severity mapped to polycystic ovary syndrome |
| title_full_unstemmed | COVID-19 biomarkers for severity mapped to polycystic ovary syndrome |
| title_short | COVID-19 biomarkers for severity mapped to polycystic ovary syndrome |
| title_sort | COVID-19 biomarkers for severity mapped to polycystic ovary syndrome |
| topic | Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Clinical sciences Large scale multi-omics analysis Biomarkers COVID-19 disease Protein panels Vessel damage Platelet degranulation Polycystic ovary syndrome (PCOS) |